Ignite Creation Date:
2024-05-06 @ 10:27 AM
Last Modification Date:
2024-10-26 @ 12:30 PM
Study NCT ID:
NCT03268954
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-30
First Post:
2017-08-30
Brief Title:
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes HR MDS Chronic Myelomonocytic Leukemia CMML or Low-Blast Acute Myelogenous Leukemia AML
Sponsor:
Takeda
Organization:
Takeda
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-11-28
Start Date Type:
ACTUAL
Primary Completion Date:
2021-05-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2017-08-30
First Submit QC Date:
August 30 2017
Study First Post Date:
2017-08-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2022-09-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-08
Last Update Post Date:
2024-04-30
Last Update Post Date Type:
ACTUAL